Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
ORTHOCELL LIMITED (OCC)ASX AI Signals has generated 1 signal(s) for OCC during the last 90 days, indicating Moderate trading activity
Latest OCC Signals | |
| 26/06/2026 | SELL |
OCC Share Price | |
| Current Price | $0.755 |
| 52 Week High | $1.530 |
| 52 Week Low: | $0.720 |
| Trading at (% of 52 Week High) | 49.35% |
Orthocell Limited (ASX: OCC) is a regenerative medicine company that develops and commercializes tissue repair products. The company specializes in cell therapy and extracellular matrix products designed to improve healing in orthopedic, wound care, and sports medicine applications.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The SELL recommendation for ORTHOCELL LIMITED (OCC) is supported by moderate bearish signals, but the confidence is tempered by limited volatility and sector-specific factors. Caution is advised given the stock's current price stability.
Orthocell records first Canadian sales of Remplir™ in US$75m market Proactive uses images sourced from Shutterstock
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has achieved first commercial sales of its flagship nerve repair device Remplir™ in Canada, marking the start of revenue generation in the country’s Orthocell to release March quarterly results, host investor webinar on April 20 Proactive uses images sourced from Shutterstock
Orthocell Ltd (ASX:OCC, OTC:ORHHF) will release its quarterly results for the period ended March 31, 2026, on Monday, April 20, and host an investor webinar the same day.
Latest ORTHOCELL LIMITED(OCC) News
Orthocell records first Canadian sales of Remplir™ in US$75m market
Orthocell to release March quarterly results, host investor webinar on April 20
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial